Avenda Health utilizes artificial intelligence to create a Cancer Estimation Map (CEM) that accurately visualizes the location and extent of prostate cancer, significantly enhancing treatment planning. This technology helps physicians make informed decisions, reducing the likelihood of residual cancer and preserving patients' quality of life.
Funding
$19.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MIPAV+1Founders
Product
Problem
Current methods of determining the location and extent of prostate cancer, such as MRI, often underestimate the geometry of the cancer, leading to inaccurate treatment planning. This can result in residual cancer or the need to treat the entire prostate, leading to unnecessary side effects and a reduced quality of life for patients.
Solution
Avenda Health's Unfold AI provides a precise Cancer Estimation Map (CEM) that visualizes the location and extent of prostate cancer in 3D, significantly improving treatment decision-making. Unfold AI analyzes standard-of-care data, including MRI, fusion biopsy, pathology, and PSA, using proprietary, FDA-cleared artificial intelligence algorithms. By providing a comprehensive map of the cancer's location relative to anatomical structures, Unfold AI enables physicians to select the correct treatment option, preserve the patient's quality of life, and reduce the likelihood of residual cancer. The technology has demonstrated superior accuracy compared to current methods in multiple clinical studies.
Target Audience
The primary target audience includes urologists, radiation oncologists, and other physicians involved in prostate cancer diagnosis and treatment, as well as patients diagnosed with Gleason Grade 2 (GG2) or greater prostate cancer who have not yet started treatment.
Features
- Generates a 3D Cancer Estimation Map (CEM) using AI analysis of patient-specific data.
- Integrates MRI, fusion biopsy, pathology reports, and PSA levels for comprehensive assessment.
- Provides visualization of cancer location and extent relative to critical anatomical structures.
- Aides in surgical planning, guiding repeat biopsies, and determining the extent of prostate treatment.
- Supports various treatment approaches, including active surveillance, prostatectomy, focal therapy, and radiotherapy.
- FDA-cleared artificial intelligence algorithms.